联合给药用于肥胖患者行无痛胃镜的安全性

Safety of Co-administration in Painless Gastroscopy for Patients with Obesity

目的观察咪达唑仑-芬太尼-丙泊酚联合用药在肥胖患者无痛胃镜检查中的效果及安全性.方法按体重指数选择门诊无痛胃镜肥胖患者168例,随机分为观察组、对照组各84例.观察组静脉给予咪唑安定0.01 mg/kg,芬太尼0.8～1μg/kg,待患者镇静后缓慢推注异丙酚1.0～1.5 mg/kg.对照组静推异丙酚2.0～2.5mg/kg.监测患者的麻醉效果、麻醉诱导时间、胃镜检查过程中呼吸循环系统并发症及异丙酚用药总量等.结果与对照组相比,观察组在诱导时间、呼吸循环系统并发症发生率及异丙酚用药总量等方面有统计学意义（P〈0.05）.观察组麻醉效果优于对照组（P〈0.05）.结论咪达唑仑-芬太尼-丙泊酚联合用药在肥胖患者无痛胃镜检查中安全可行.

Objective To observe the efficacy and safety of combination therapy with midazolam-fentanyl-propofol in painless gastroscopy for obese patients. Methods According to body mass index, 168 obese patients underwent were randomly divided into two groups： control group and Observation group, 84 cases in each group. Patients in the observation group were given intravenous midazolam 0.01 mg/kg, fentanyl 0.8 - 1 μg/kg, and slow injection of propofol 1.0 - 1.5 mg/kg after sedation. Patients in the control group were given injection of propofol 2.0 - 2.5 mg/kg. Then we monitored the patient＇s anesthesia, anesthesia induction time, respiratory and circulatory complications and the total amount of propofol and other drugs during gastroscopy. Results Compared with the control group, the observation group at the induction time, aspects of the respiratory and circulatory systems of the total incidence of complications and propofol and other drugs had statistically significant difference （P〈0.05） . Anesthetic effect in the observation group was better than the control group （P 〈0.05） Conclusion Midazolam-fentanyl-propofol combination therapy is feasible and safe in painless gastroscopy for obese patients.